SS-31 (Elamipretide) · Research brief

Best SS-31 Dosage Mitochondrial Function 2026 Guide

Real Peptides Research TeamEditorial

Updated April 28, 20269 min read

59 WORDS

Short answer

Research from Stealth BioTherapeutics' Phase 2 trials showed that SS-31 (elamipretide) at 40mg daily produced significant improvements in left ventricular end-diastolic volume in Barth syndrome patients. But the same dose failed to show statistical significance in primary mitochondrial myopathy trials. The difference wasn't the compound. It was the underlying mitochondrial dysfunction pattern and dosing schedule relative to disease pathology.

Key takeaways

SS-31 efficacy depends on cardiolipin saturation, not linear dose scaling. Once binding sites saturate, additional peptide provides no additional benefit.
The best SS-31 dosage for mitochondrial function in 2026 ranges 0.25–5mg/kg based on tissue cardiolipin density, with cardiac applications requiring 4–5mg/kg and neuroprotection effective at 0.5–1mg/kg.
Subcutaneous delivery at twice-daily intervals outperforms single daily IV for chronic mitochondrial dysfunction because the peptide's 3–4 hour half-life requires sustained plasma levels.
Clinical trials used 40mg daily (roughly 0.5–0.6mg/kg in adults) for Barth syndrome with significant cardiac improvement but minimal skeletal muscle response.
Timing relative to oxidative stress events matters more than total daily dose. Pre-treatment 30–60 minutes before anticipated injury consistently outperforms post-injury administration.
Oral SS-31 formulations lack credible bioavailability data. The peptide's charge profile and structure make intestinal absorption negligible.

Our team has worked with hundreds of researchers running SS-31 protocols across cellular models, animal studies, and human clinical applications. The gap between effective dosing and wasted compound comes down to three factors most dosing guides never address: membrane saturation kinetics, cardiolipin density in target tissue, and the timing relationship between oxidative stress peaks and peptide availability.

What is the best SS-31 dosage for mitochondrial function in 2026?

The best SS-31 dosage for mitochondrial function in 2026 ranges from 0.25mg/kg to 5mg/kg depending on target outcome, delivery route, and tissue-specific cardiolipin content. Clinical trials demonstrate efficacy at 40mg daily IV for cardiac applications, while preclinical models show neuroprotective effects at subcutaneous doses as low as 3mg/kg. Optimal results require matched dosing frequency to the half-life of approximately 3–4 hours and timing relative to anticipated oxidative stress events.

Most researchers assume higher doses produce proportionally better outcomes, but SS-31's mechanism doesn't scale linearly. The peptide works by binding cardiolipin. A phospholipid exclusively found in the inner mitochondrial membrane. To stabilise cristae structure and reduce electron leak during oxidative phosphorylation. Once cardiolipin binding sites saturate, additional peptide circulates without additional benefit. This article covers the dose ranges validated in published trials, the tissue-specific variables that determine optimal protocols, and the timing strategies that separate functional mitochondrial rescue from expensive placebo.

SS-31 Dosing Ranges Across Research Applications

The best SS-31 dosage mitochondrial function outcomes come from matching dose to cardiolipin density and oxidative injury severity. Published research spans three distinct dose tiers.

Low-dose protocols (0.25–1mg/kg subcutaneous) dominate neuroprotection studies. A 2022 study in Neurobiology of Disease used 0.5mg/kg SS-31 administered 30 minutes before ischemic stroke induction in rats and demonstrated 40% reduction in infarct volume compared to saline controls. The mechanism: SS-31 binds cardiolipin in neuronal mitochondria before ATP depletion triggers cristae remodelling. The structural change that commits cells to apoptosis. Timing matters more than total dose in acute injury models because cardiolipin exposure on the outer mitochondrial membrane peaks during the first 2–4 hours post-injury.

Mid-range protocols (1–3mg/kg subcutaneous or IV) appear in metabolic and age-related research. Dai et al. (2020) used 3mg/kg daily SS-31 in aged mice for 8 weeks and reported restored skeletal muscle mitochondrial respiration to levels indistinguishable from young controls, alongside 15% improvement in exercise capacity. The outcome wasn't driven by mitochondrial biogenesis. Total mitochondrial content remained unchanged. SS-31 improved existing mitochondrial efficiency by reducing superoxide production at Complex I and III, the primary sites of age-related electron leak.

High-dose clinical protocols (40mg daily IV or 4mg/kg equivalent) defined the Barth syndrome and primary mitochondrial myopathy trials. The TAZPOWER trial used 40mg daily elamipretide via subcutaneous injection in Barth patients with severe cardiomyopathy. Left ventricular stroke volume improved significantly, but skeletal muscle strength. The secondary endpoint. Did not. The differential response reflects tissue-specific cardiolipin isoform distribution: cardiac tissue has 5–6× the cardiolipin content of skeletal muscle, meaning the same circulating dose produces stronger functional rescue in heart versus limb.

Our experience with researchers indicates the most common dosing error is applying cardiac-optimised protocols to non-cardiac targets without adjusting for tissue cardiolipin density.

Delivery Route and Bioavailability Considerations

SS-31's mitochondrial targeting depends on maintaining plasma concentrations above the threshold required for inner membrane translocation. Approximately 50–100nM based on cell culture models. Delivery route determines whether that threshold is sustained long enough to saturate available cardiolipin binding sites.

Intravenous administration produces immediate peak plasma concentration but rapid clearance. Pharmacokinetic data from Stealth BioTherapeutics show SS-31 half-life of 3–4 hours following IV bolus. For acute applications. Ischemia-reperfusion injury, sepsis models, acute kidney injury. IV delivers the peptide exactly when oxidative burst occurs. The 2019 study by Szeto et al. in Journal of the American Society of Nephrology used a single 5mg/kg IV dose of SS-31 30 minutes before renal artery clamping in rats and reduced tubular necrosis by 60% compared to vehicle. Repeat dosing wasn't required because the injury was time-limited.

Subcutaneous injection extends peptide availability through slower absorption kinetics. The same total dose given SC maintains detectable plasma levels 50% longer than IV, making it preferable for chronic conditions where mitochondrial dysfunction persists across days or weeks. Researchers working with neurodegenerative models consistently see better outcomes with twice-daily SC dosing (morning and evening) versus single daily IV. Not because more peptide enters circulation, but because the peptide is present during both the daytime activity-induced oxidative stress peak and the nocturnal autophagic clearance window.

Oral delivery remains unvalidated for SS-31. The peptide's four positive charges and aromatic dimethyltyrosine residue make intestinal absorption negligible. Some supplement vendors market 'mitochondrial support peptides' for oral use. Those are not SS-31, and the claimed bioavailability is structurally implausible.

Here's what we've learned working with labs running SS-31 protocols: if your model involves predictable oxidative events (exercise, toxin exposure, ischemia), dose 30–60 minutes before the event. If the injury is chronic and unpredictable, dose twice daily to maintain coverage.

SS-31 Dosage Mitochondrial Function 2026: Protocol Comparison

Application	Dose Range	Route	Frequency	Key Outcome	Bottom Line
Acute ischemia (cardiac, renal, CNS)	3–5mg/kg	IV bolus	Single dose pre-injury	40–60% reduction in tissue necrosis vs control	Timing trumps dose. Administer 30–60 min before anticipated oxidative event
Neurodegenerative models (chronic)	0.5–1mg/kg	SC	Twice daily	Preserved motor function, reduced ROS markers	Low-dose frequent beats high-dose sporadic for sustained neuroprotection
Metabolic / age-related dysfunction	3mg/kg	SC	Once daily	Restored mitochondrial respiration, improved exercise capacity	8+ weeks required for functional outcomes. Single-dose studies show mechanism only
Barth syndrome / cardiolipin deficiency	40mg (fixed) or 4mg/kg	SC or IV	Once daily	Improved LV stroke volume, reduced NT-proBNP	High cardiolipin-density tissues respond to higher doses; skeletal muscle does not
Sepsis / ARDS models	5mg/kg	IV	Single or q12h × 3 days	Reduced organ failure scores, improved survival	Acute high-dose outperforms chronic low-dose in cytokine storm contexts

What If: SS-31 Dosing Scenarios

What If I'm Designing a Protocol for Acute Ischemic Injury?

Use 3–5mg/kg IV bolus administered 30–60 minutes before anticipated ischemia. The mechanism requires SS-31 presence in mitochondria before ATP depletion triggers cristae remodelling. Post-injury dosing reduces efficacy by 50% or more. If the injury timing is unpredictable, switch to twice-daily SC dosing at 1–2mg/kg to maintain baseline protection.

What If the Target Tissue Has Low Cardiolipin Content?

Skeletal muscle, liver, and adipose tissue contain 60–80% less cardiolipin than cardiac or renal tissue. Lower your dose to 0.5–1mg/kg and increase frequency rather than raising total amount. Excess peptide won't bind and simply clears through renal excretion. Functional outcomes in low-cardiolipin tissues require 4+ weeks of consistent dosing because the effect accumulates through reduced chronic oxidative damage, not acute rescue.

What If I'm Comparing SS-31 to MitoQ or SkQ1?

SS-31 binds cardiolipin reversibly without redox activity. It's a structural stabiliser, not an antioxidant. MitoQ and SkQ1 deliver CoQ10 or plastoquinone to mitochondria and work through direct ROS scavenging. SS-31 outperforms lipophilic antioxidants in models where cristae structure collapse drives pathology (Barth syndrome, ischemia-reperfusion), while MitoQ shows stronger effects in models driven purely by oxidative damage without structural defects. Don't assume they're interchangeable. The mechanisms target different steps in mitochondrial failure.

The Clinical Truth About SS-31 Dosing

Here's the honest answer: most SS-31 research uses doses that worked in the first published model without validating whether that dose is optimal for the new application. The 3mg/kg dose appears in dozens of papers not because it's mechanistically ideal. It's there because Szeto's original 2011 paper used it and showed an effect.

The evidence is clear: SS-31 efficacy depends on tissue-specific cardiolipin availability, oxidative injury timing, and plasma concentration duration. A dose that rescues cardiac function in Barth syndrome won't produce the same magnitude of benefit in skeletal muscle because the cardiolipin content differs by 5-fold. Researchers who assume 'more is better' waste compound. And worse, miss the real variable, which is dosing frequency relative to the peptide's 3–4 hour half-life.

We mean this sincerely: if you're designing an SS-31 protocol, start with tissue cardiolipin density, not the dose from the last paper you read. High-cardiolipin tissues (heart, kidney, brain, brown adipose) respond to single daily dosing at 3–5mg/kg. Low-cardiolipin tissues (skeletal muscle, liver, white adipose) require twice-daily dosing at 0.5–1mg/kg to see functional outcomes. The peptide works. But only when the protocol matches the biology.

Dosing Strategy Integration With Real Peptides

Researchers working with mitochondrial-targeted compounds benefit from consistent peptide purity and reliable synthesis protocols. Our dedication to small-batch synthesis with exact amino-acid sequencing extends across the entire research peptide catalogue. When you're validating dose-response relationships in SS-31 studies, batch-to-batch variability in peptide purity introduces confounding variables that skew EC50 calculations and obscure true therapeutic windows. Facilities designing protocols around compounds like Thymalin or Cerebrolysin understand this. Mitochondrial function assays are exquisitely sensitive to impurities that standard HPLC might not flag.

The best SS-31 dosage mitochondrial function outcomes in 2026 depend as much on peptide integrity as on protocol design. Dosing precision becomes irrelevant if the peptide you're dosing contains truncated sequences or oxidised residues that can't bind cardiolipin properly. Every batch we prepare undergoes mass spectrometry verification to confirm the exact molecular weight matches the target sequence. There's no tolerance for 'close enough' when the mechanism depends on four specific positive charges interacting with anionic phospholipid headgroups. Researchers who've switched to verified-purity sources report tighter dose-response curves and more reproducible mitochondrial respiration data, particularly in assays measuring Complex I and III activity where SS-31's effect is most pronounced.

SS-31 remains one of the most mechanistically elegant mitochondrial interventions available. But it only works when dosed with precision relative to the biology you're targeting. The clinical trials that failed didn't fail because the peptide doesn't work. They failed because the dose, timing, or tissue match wasn't optimised for the specific cardiolipin pathology at hand.

FAQ Section

References

Peer-reviewed sources on SS-31 (Elamipretide) indexed in PubMed, listed for research context. Real Peptides supplies SS-31 (Elamipretide) for laboratory research use only.

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences, 2025. PMID 39940712. doi:10.3390/ijms26030944
Elamipretide: First Approval. Drugs, 2026. PMID 41335372. doi:10.1007/s40265-025-02269-8
SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. PMID 41136322. doi:10.1016/j.neurot.2025.e00772
SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110. doi:10.1016/j.biopha.2025.117832
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 40294492. doi:10.1016/j.biopha.2025.118056
SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function. Organogenesis, 2025. PMID 40570323. doi:10.1080/15476278.2025.2519649
Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31. Journal of the American Society of Nephrology : JASN, 2024. PMID 38530359. doi:10.1681/ASN.0000000000000338
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181. doi:10.1016/j.gim.2024.101138

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Clinical trials in Barth syndrome used 40mg daily elamipretide (SS-31) via subcutaneous injection, which translates to approximately 0.5–0.6mg/kg in adults. However, preclinical cardiac ischemia models demonstrate efficacy at higher doses of 3–5mg/kg IV when administered 30–60 minutes before ischemic injury. Cardiac tissue contains exceptionally high cardiolipin density compared to other tissues, which allows it to respond to higher SS-31 concentrations — the peptide saturates available cardiolipin binding sites more completely at these elevated doses, producing measurable improvements in left ventricular function and reduced infarct size.

SS-31 cannot be taken orally with meaningful bioavailability. The peptide contains four positively charged amino acids and a bulky aromatic dimethyltyrosine residue, which make intestinal absorption negligible under physiological pH conditions. All published research demonstrating mitochondrial function improvements used either intravenous or subcutaneous delivery routes. Products marketed as oral mitochondrial peptides are not SS-31 — the structural chemistry does not support claims of oral bioavailability for this specific compound.

Acute injury models (ischemia-reperfusion, sepsis, acute kidney injury) respond to single high-dose IV administration of 3–5mg/kg given 30–60 minutes before the anticipated oxidative event. Chronic mitochondrial dysfunction models (aging, neurodegenerative disease, metabolic disorders) require lower doses of 0.5–3mg/kg administered subcutaneously once or twice daily for 4–8 weeks. The difference reflects timing: acute protocols exploit SS-31’s ability to prevent cristae collapse during a discrete oxidative burst, while chronic protocols rely on sustained reduction in baseline electron leak over extended periods.

Clinical trials using 40mg daily elamipretide reported adverse events in fewer than 10% of participants, with injection site reactions being the most common. No dose-limiting toxicity was identified in Phase 2 trials. Preclinical studies using doses up to 10mg/kg showed no organ toxicity or behavioural changes in rodents over 12-week treatment periods. SS-31’s mechanism — reversible cardiolipin binding without redox activity — limits off-target effects compared to mitochondrial antioxidants that can interfere with physiological ROS signalling.

The primary mitochondrial myopathy trials failed to meet primary endpoints not because SS-31 lacks efficacy, but because the dose and tissue match were suboptimal. Skeletal muscle contains significantly less cardiolipin than cardiac tissue — the 40mg daily dose that improved heart function in Barth syndrome patients was insufficient to saturate cardiolipin sites in skeletal muscle. Additionally, trial designs did not account for SS-31’s short half-life of 3–4 hours; once-daily dosing may not maintain therapeutic plasma levels long enough to produce sustained skeletal muscle benefits.

Acute injury models show mitochondrial protection within 1–2 hours of SS-31 administration, measurable as reduced cytochrome c release and preserved ATP levels. Chronic applications require 4–8 weeks of consistent dosing to produce functional outcomes like improved exercise capacity or reduced oxidative stress markers. The timeline reflects the difference between preventing acute mitochondrial damage (immediate) versus reversing accumulated chronic dysfunction (weeks). Studies measuring mitochondrial respiration rates show detectable improvements within 2–3 weeks at doses of 3mg/kg daily.

Most preclinical protocols use weight-based dosing (mg/kg), while clinical trials used fixed doses (40mg daily) regardless of body weight. For research applications, weight-based dosing ensures consistent tissue exposure across subjects. Aged animals respond to the same mg/kg doses as young animals — the peptide’s mechanism does not appear to be affected by age-related changes in drug metabolism. However, tissues with pre-existing severe mitochondrial damage may require longer treatment duration rather than higher doses to achieve functional rescue.

SS-31 has been studied in combination with NAD+ precursors, coenzyme Q10, and alpha-lipoic acid in preclinical models without adverse interactions. Because SS-31 works through structural cardiolipin stabilisation rather than redox chemistry, it complements rather than competes with therapies that enhance electron transport chain function or scavenge ROS. However, combining SS-31 with other mitochondrial membrane-active compounds requires careful consideration of cumulative effects on membrane potential and cristae architecture.

SS-31 (elamipretide) is the only Szeto-Schiller peptide series compound that binds cardiolipin with high affinity and has advanced to clinical trials. SS-20 and SS-02 are earlier-generation analogues with different aromatic residues that showed weaker cardiolipin binding and less robust mitochondrial protection in head-to-head comparisons. SS-31’s specific sequence — Dmt-D-Arg-Phe-Lys-NH2 — produces optimal electrostatic interaction with cardiolipin’s anionic headgroups while maintaining cell permeability. Other peptides in the series are primarily used as negative controls in research rather than therapeutic candidates.

Lyophilised SS-31 should be stored at −20°C in a desiccated environment to prevent moisture absorption and oxidative degradation. Once reconstituted in sterile water or saline, the peptide solution remains stable at 2–8°C for up to 4 weeks based on HPLC purity assays. Avoid repeated freeze-thaw cycles of reconstituted peptide, as this can induce aggregation and reduce bioactivity. For long-term storage of reconstituted aliquots, snap-freeze in liquid nitrogen and store at −80°C — this maintains >95% purity for 6+ months.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA